Eikon Therapeutics
About Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company focused on advancing breakthrough therapeutics through the purposeful integration of science and engineering. It emphasizes innovative approaches at the intersection of biology and engineering to accelerate drug discovery and development. The company operates with a footprint in the United States, including locations in Millbrae, California, New York, New York, and Jersey City, New Jersey, reflecting a multi-site research and development presence.
Recent News
The 5 Largest IPOs in Biopharma History
STAT+: A Sign Biotech Is Back? Four Drugmakers Go Public, Raising Nearly $1 Billion in All
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
Merck’s PD-1/VEGF Data Star in Stacked Lineup of AACR ‘26 Data Reveals
Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
Eikon IPO Analysis: Big Biotech Names, Big Valuation Cut
Eikon Prices Its IPO, Seeking to Raise $318m
Eikon, a High-Profile Startup Led by Merck Vets, Seeks an IPO
2026 IPO Train Keeps Chugging as AgomAb, SpyGlass Eye Nasdaq Debut
Three More Biotechs Price Their Nasdaq IPOs